We sought to evaluate the impact of intermediate creatine kinase-myocardial band isoenzyme (CK-MB) elevation on late clinical outcomes in patients undergoing successful stent implantation in native coronary arteries.
There is significant controversy regarding the prognostic importance of mild-to-moderate creatine kinasemyocardial band isoenzyme (CK-MB) increase (Ͼ1 to 5
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times normal) after percutaneous coronary interventions of native coronary lesions. This issue requires further evaluation, especially as abnormal elevation of enzyme markers occurs frequently after instrumentation of coronary arteries. Creatine kinase-myocardial band isoenzyme elevation has been reported in up to 22% of overall coronary interventions (1) (2) (3) (4) (5) (6) (7) (8) (9) and even as high as 47% following successful vein graft angioplasty (10) . Recent studies have reported that intermediate creatine kinase (CK) elevations in patients undergoing successful coronary angioplasty or directional atherectomy are associated with an adverse long-term outcome, including cardiac death (11, 12) . Other reports, however, have shown that modest CK-MB isoform elevation after coronary stenting or directional atherectomy has no adverse clinical consequences and therefore should not be considered a major complication (13) . Thus, the objective of the present study was to evaluate the incidence and longterm clinical outcome of patients with CK-MB elevation after stenting of native coronary arteries, and to determine whether rise of CK-MB levels after elective stenting is an independent predictor of unfavorable long-term clinical outcomes.
METHODS

Patient population.
All 900 patients (1,213 lesions) who underwent successful, elective native coronary artery stenting between January 1994 and December 1995 were selected for this analysis. Stents used in this cohort included the Gianturco-Roubin, the coronary Palmaz-Schatz and the biliary Palmaz stents.
Techniques of coronary stenting. Patients were selected for coronary stenting by the operator based on preintervention lesion characteristics. All patients were premedicated with 325 mg of aspirin prior to the procedure, unless contraindicated. Bolus intravenous (IV) heparin, 10,000 to 15,000 U, was given after sheath insertion. Additional heparin boluses were given to maintain the HemoTech activated clotting time Ͼ300 s. Patients also received ticlopidine with or without the addition of low-molecularweight heparin or warfarin (Coumadin) at the end of the procedure. Patients were excluded for this analysis if they had received glycoprotein IIb/IIIa inhibitor.
CK-MB determination. All patients had serial measurements of CK-MB isoform at baseline, 6 h and 18 to 24 h after coronary intervention. Patients with baseline CK-MB isoform elevation were excluded from this analysis if the levels were elevated. Absolute CK-MB levels were determined by radioimmunoassay (normal Յ4 ng/ml) (Dade Behring Inc., Miami, Florida). When the CK-MB level was elevated, it was monitored every 8 h until it came back to normal values. Patients were classified according to the peak CK-MB values into three groups: group 1 had no CK-MB elevation following the procedure, group 2 had an elevation of CK-MB Ͼ1 to 5 times normal (5 to 20 ng/ml) and group 3 had a CK-MB increase Ͼ5 times normal (Ͼ20 ng/ml).
Clinical and procedural variables. Baseline demographic and procedural variables were recorded prospectively and entered in the Cardiology Research Foundation Database. All patients included in this analysis underwent successful coronary intervention as defined by Ͻ50% residual diameter stenosis and the absence of death, Q-wave myocardial infarction or emergency or urgent coronary bypass surgery. The occurrence of minor or major complications, including subacute closure, recurrent chest pain, ischemia or repeat coronary intervention, was also recorded.
Angiographic analysis. All cineangiograms were analyzed in blinded manner with regard to the acute clinical outcome and CK-MB level. Flow was graded according to Thrombolysis in Myocardial Infarction (TIMI) study criteria; TIMI flow grade 0 or 1 was considered representative of a total occlusion. The rest of the angiographic definitions used in this study have been published previously (3) . Angiographic measurements before and after the procedure were performed using hand-held calipers in the projection showing the most severe stenosis (worst view), with the guiding catheter serving as the reference standard.
Clinical Follow-up and end points. Trained personnel followed up patients in outpatient visits and by telephone calls. The patients were contacted three, six and 12 months after their procedure and yearly thereafter. The patients were questioned as to recurrence or presence of cardiovascular symptoms (myocardial infarction [MI] , angina, heart failure and arrhythmias) or the need for repeat coronary revascularization. For patients with clinical events, their medical records were reviewed and the events were adjudicated. The families or the physicians of deceased patients were interviewed to try to determine the cause of death. Patients were followed up for a mean of 14 months and data were obtained in 96% of patients. The primary end point of the study was the occurrence of death at one year. Secondary end points included TLR and the combined occurrence of death/Q-wave MI/and death/Q-wave MI/coronary artery bypass grafting (CABG) percutaneous transluminal coronary angioplasty (PTCA) at one year.
Statistics. All statistical analyses were performed using statistical software (SAS; SAS Institute; Cary, North Carolina). Continuous variables are presented as mean Ϯ SD and categorical variables are presented as percentages. One-way analysis of variance (ANOVA) was used to determine differences in the three groups. Comparisons between two groups were made using the chi-square test or the Fisher exact test to analyze differences in categorical variables, and t test for continuous variables with a Bonferroni correction. are presented in Table 1 . Most patients were men with unstable angina and a high prevalence of risk factors. Patients in group 1 were younger (p Ͻ 0.01), more frequently male (p Ͻ 0.01), had higher left ventricular ejection fraction (p ϭ 0.02), more often had a history of PTCA (p ϭ 0.04) and presented less frequently with unstable angina (p ϭ 0.006) and history of MI (p ϭ 0.05) than patients in either group 2 or 3.
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Lesion characteristics. Lesion configuration is summarized in Table 2 . Patients in group 3 presented with more de novo lesions (p ϭ 0.001), totally occluded vessels (p ϭ 0.001) and type C lesions than those in group 1. Patients in group 2 had more ostial lesions (p ϭ 0.03), a trend toward more total occlusions (p ϭ 0.19) and less restenotic (p ϭ 0.02) and eccentric lesions (p ϭ 0.005) than patients in group 1.
Procedural variables. In Table 3 , procedural variables are shown. Patients in group 1 had more lesions treated in the right coronary artery (p Ͻ 0.01), less number of stents per lesion (p Ͻ 0.01) and more Palmaz-Schatz coronary stents used (p Ͻ 0.01) than patients in the other two groups. Patients in group 3 had a larger final minimal lumen diameter (p ϭ 0.05), smaller final percent diameter stenosis (p ϭ 0.01), more stents per lesion (p ϭ 0.002) and more Gianturco-Roubin flexible coronary stents (p ϭ 0.001) than patients in group 1. No differences were observed in the reference vessel diameter in any of the three groups. Early outcome. In-hospital outcome by CK-MB level is presented in Table 4 . By inclusion criteria, all patients in this analysis had a successful procedure defined as an increase of Ͼ20% in luminal diameter with final percent diameter stenosis of Ͻ50%, without the occurrence of any major complication (death, Q-wave MI and CABG). The peak CK-MB levels were 1.1 Ϯ 1.0 ng/ml, 8.1 Ϯ 3.8 ng/ml and 53.5 Ϯ 41.7 ng/ml in groups 1, 2 and 3, respectively. Late outcome. The late clinical events are summarized in Table 5 . Long-term clinical end points were similar in patients in groups 1 and 2. A trend toward more CABG but less PTCA was observed in group 2. However, patients in group 3 had an increased incidence of late mortality when compared with those in group 2 and 1 (6.9%, 1.2% and 1.7%, respectively, p ϭ 0.01 by ANOVA). Q-wave MI was also more common in this group (4.1%, 0.8% and 1.0%, respectively, p Ͻ 0.01) as it was also the composite end point of death/Q-wave MI/CABG/PTCA (37.5%, 24.3% and 24.9%, p Ͻ 0.05). Multivariate analysis (Table 6) showed that patients with CK-MB Ͼ5 times normal after coronary stenting had an increased risk of major adverse clinical events (relative risk [RR]: 1.70, p Ͻ 0.05), which was not observed in patients with minor CK-MB elevation (RR: 0.89, p ϭ 0.5). Also, patients in group 3 had a higher risk of death (p ϭ 0.04) or death and MI (p ϭ 0.03) by logistic regression analysis.
DISCUSSION
The results of the present study indicate that the incidence of CK-MB elevation following successful stenting in native coronary arteries is relatively high (35%). Most of these patients (26.4%) experienced a CK-MB rise between 1 to 5 times normal. We found that while major elevation of CK-MB (Ͼ5 times normal) predicts a higher risk of death and late major adverse clinical events, lower elevations are not associated with an unfavorable long-term outcome. The importance of this issue is emphasized by the fact that new drugs (i.e., glycoprotein IIb/IIIa antagonists) have been shown to improve clinical outcomes following percutaneous coronary revascularization mainly by reducing the incidence of non-Q-wave MI (14 -16).
Previous studies. Unfavorable prognostic importance of CK or CK-MB elevations on late clinical outcomes after percutaneous coronary revascularization has been reported in three studies (1, 12, 17) . Harrington et al. (1) reported the consequences of MI in 1,012 patients enrolled in the Coronary Angioplasty versus Excisional Atherectomy Trial (CAVEAT). Myocardial infarction was defined as new pathologic Q waves, CK-MB levels three or more times the upper limit of normal or total CK levels two or more times the upper limit of normal (when CK-MB levels were not available). The authors reported an increased risk of death at one year in patients with MI when baseline characteristics were considered (p ϭ 0.038). However, only borderline significance was observed when baseline characteristics and (17) followed up 253 patients with total CK and CK-MB fraction elevation and 120 control patients without CK elevation after PTCA. They found that late cardiac mortality was greater (p ϭ 0.02) for patients with CK elevation after PTCA. It was also reported that when patients were categorized according to peak CK elevation, cardiac mortality was significantly higher with high (Ͼ3.0 times normal) and minor (1.5 to 3.0 times normal) CK rise (p ϭ 0.007) (17) .
Comparison between this and other studies. Even though previous studies included a broad range of interventional devices, patients with coronary stents were not included in their analysis. No quantitative coronary angiography data were presented, thus the influence of final minimal lumen diameter or final percent diameter stenosis on clinical end points could not be assessed, and patients with interventions in saphenous vein grafts were not excluded. Finally, data from the IMPACT II trial associated increased levels of CK-MB with major adverse clinical events, but the death rate did not seem to be higher for patients with CK-MB elevation Ͼ5 times normal (19) . Our results disagree with the increased mortality associated with mild-to-moderate elevation of CK or CK-MB after PTCA observed in these studies (12, 17) . However, our report confirms the increased risk of death and major clinical events seen in patients with major CK-MB elevation (Ͼ5 times normal) (12, 13, 17, 19) . However, significant data have shown no association between cardiac enzyme elevation after percutaneous coronary revascularization and adverse clinical outcomes. Oh et al. (7) reported on 25 of 128 patients (20%) who had CK-MB elevation following PTCA. At a mean follow-up of 10 months, no early or late mortality was observed in any patient with or without elevation of CK-MB (8 (23) . Indeed, in our report, patients with CK-MB elevation seemed to be a population at higher risk of complications. When compared with group 1, patients in group 2 had higher incidence of diabetes (p ϭ 0.12) and unstable angina (p ϭ 0.006), both strongly associated with a higher risk of major adverse clinical events in our multivariate analysis. Furthermore, patients in group 2 had a higher incidence of in-hospital ischemic events (recurrent typical chest pain, repeat catheterization and pulmonary edema). Similarly, patients in group 3 had lower left ventricular function, higher incidence of adverse lesion characteristics and marked increase of early complications and thus greater number of late ischemic events (Tables 4 and 5 ). Thus, it may be that despite adjusting for all known risk factors for cardiac mortality, patients with very high CK elevation had more extensive disease that could not be accounted for by standard methods (24) . It must be noted in our results, however, that despite all these clinical disadvantages of patients in group 2 (intermediate elevation of CK-MB), the late occurrence of death, MI or the composite end point (death, MI, CABG and PTCA) was almost identical to that of patients in group 1.
Native vessels versus saphenous vein graft. Our study differs from previous reports in that only consecutive patients undergoing stenting of native vessels were included. It must be noted that in previous analyses, patients who had higher CK or CK-MB elevations had interventions more frequently in saphenous vein grafts (12, 17) . Late mortality after percutaneous revascularization of saphenous vein conduits is higher than that of native coronary arteries (25) . In the study of Kong et al. (17) , saphenous vein graft PTCA was the most important predictor of long-term cardiac mortality or subsequent MI (RR 3.59, p Ͻ 0.001). Indeed, if we compare our report (native vessels) with that of patients undergoing revascularization of vein grafts during the same time period and by the same operators, the incidence of late mortality seems to be much higher in the latter for each level of CK-MB (normal CK-MB 1.7% vs. 4.8%, CK-MB 5 to 20 ng/ml 1.2% vs. 6.5%, CK-MB Ͼ20 ng/ml 6.9% vs. 11.7%) (10) . Thus, by analyzing only interventions in native vessels, we were able to exclude the important potential confounding effect of saphenous vein graft revascularization.
Stents and CK-MB elevation. According to a national cardiovascular network, while the use of directional and rotational atherectomy decreased 30% to 50% between 1994 and 1996, that of coronary stents increased fivefold during the same time period (26) and its use will most likely increase in the future, especially with improved designs. Despite this, little is known about the incidence and significance of cardiac enzyme marker elevation after coronary stenting. In fact, as most previous reports have not included patients undergoing coronary stenting in their analyses, their findings cannot necessarily be extrapolated to this revascularization technique (1, 11, 12, 17) . We report an incidence of 26% intermediate CK-MB elevation and 8% of high CK-MB elevation after stenting in native coronary arteries. This incidence is higher than 11.5% CK-MB elevation Ͼ10 IU/liter reported following directional atherectomy and stenting in one series (13) or to the more recent 22% in patients enrolled in the STARS trial (20) . We believe that our results may represent more accurately the incidence of any CK-MB elevation after successful native coronary artery stenting in a daily and more current interventional practice. However, it must be kept in mind that the definition of CK-MB was very strict and that patients treated with Gp IIb/IIIa inhibitors were excluded from this analysis. Finally, despite the difference in the stent model used in each group, we did not observe an association between stent model and late clinical events by multivariate analysis.
CONCLUSION
Creatine kinase-myocardial band isoenzyme elevation occurs frequently following stenting in native coronary arteries. Patients with CK-MB elevation Ͼ5 times normal had higher mortality rate and lower event-free survival at follow-up than those patients with normal or intermediate CK-MB elevation. Despite unfavorable baseline clinical characteristics, patients with intermediate CK-MB elevation did not experience an increased risk of late mortality or major adverse clinical events after coronary stenting when compared to patients with no CK-MB elevation.
